Pfizer Reports real-world evidence Data for Palbociclib in Endometrial cancer

Pfizer today announced real-world evidence results for palbociclib in patients with endometrial cancer. The study demonstrated that palbociclib reduces exacerbation rates compared to standard of care or placebo. These results provide important insights into the treatment of endometrial cancer and support the continued development of palbociclib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.